Latest Commercialization News

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

WhiteHawk Limited has raised A$1.5 million through a share placement to fund integration and growth of its newly acquired Quixxi Clarity AI platform, marking a strategic push into the AI governance market.

Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Hiremii Limited has landed its initial paying customers for its AI-powered workforce intelligence platform, marking a pivotal step in its shift from recruitment services to a SaaS technology provider in energy and infrastructure sectors.

OD6 Metals has revealed exceptional channel sampling results from its Horseshoe Prospect within the Quinn Fluorspar Project, confirming extensive ultra-high-grade fluorspar mineralisation with grades peaking at 82% CaF2. These findings underscore the project's potential for direct shipping ore and acid-grade fluorspar production.

Genetic Signatures has locked in a 10-year supply deal with Denmark’s Hvidovre Hospital for its EasyScreen™ Pan-Enteric assay, marking a significant step in its European expansion. The agreement covers 28,000 tests in the first year with growth expected, leveraging the company’s proprietary 3base® technology to streamline complex gastrointestinal pathogen detection.

Vysarn Limited's joint venture with Kariyarra Aboriginal Corporation has been shortlisted by Water Corporation to submit a formal proposal for supplying bulk water to Port Hedland, progressing key regulatory approvals for the Kariyarra Water Scheme.

Finbar has completed settlement on a prime West Leederville site and lodged a development application for a $230 million mixed-use project featuring 240 apartments and commercial space, aiming for earnings impact in FY2029/FY2030.

Hazer Group and KBR have completed a commercial-scale Process Design Package for a 30,000 tonnes per annum hydrogen plant, marking a key step toward industrial deployment of methane pyrolysis technology.

Bindi Metals has identified extensive bonanza-grade gold mineralisation across a 3 km corridor at its Ravni Project in Serbia, with new high-grade surface results and large soil anomalies expanding the system footprint. The company is advancing rapidly toward its maiden drilling campaign.

AVITA Medical’s Cohealyx-I study interim results show a significant acceleration in skin grafting time for full-thickness wounds, reducing mean time to graft from 33.2 to 13.6 days. The ongoing trial’s promising data could reshape wound care protocols.